Comparison 3. SPLINT VERSUS ORAL STEROID.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 CTS symptoms (BCTQ)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1.1 Short‐term improvement: 3 months or less	1	71	Mean Difference (IV, Random, 95% CI)	0.25 [‐0.03, 0.53]
3.2 Function (BCTQ)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.2.1 Short‐term improvement: 3 months or less	1	71	Mean Difference (IV, Random, 95% CI)	0.12 [‐0.06, 0.30]
3.3 Adverse effects	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.3.1 Adverse effects	1	71	Risk Ratio (M‐H, Random, 95% CI)	4.86 [0.24, 97.86]